.jpeg)
2026-09-18 05:26:29
Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist for adults with type 2 diabetes–related chronic kidney disease and for heart failure with LVEF≥40%. Start by eGFR, titrate by serum potassium, monitor UACR, renal function, and hyperkalemia risk.
2026-09-02 05:52:04
Finerenone is a non-steroidal selective mineralocorticoid receptor antagonist for chronic kidney disease associated with type 2 diabetes and for heart failure with LVEF ≥40%, adding a third pathway alongside RAAS and SGLT2 inhibitors.
2026-07-22 04:17:54
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates endogenous erythropoietin production by mimicking the physiological response to hypoxia, offering an injection-free treatment option for patients with chronic kidney disease-related anemia. This article systematically reviews its mechanism of action, clinical efficacy, and safety profile.
2026-06-08 03:41:19
An in-depth guide to Daprodustat (HIF-PHI) drug interactions, covering metabolic pathways involving CYP2C8/CYP3A4, contraindications with other medications, and necessary dose adjustments.
2026-06-03 03:01:52
This article introduces vadadustat, an oral HIF-PH inhibitor, explaining its dual mechanism of raising hemoglobin and improving iron utilization. It highlights the treatment convenience and potential cardiovascular safety benefits it offers to patients with anemia of chronic kidney disease.
2026-04-23 05:18:55
Finerenone is a groundbreaking therapy designed for patients with type 2 diabetes and chronic kidney disease. Learn about its mechanism, indications, and cardiovascular benefits in slowing kidney decline and reducing heart risks.
2026-04-21 03:28:51
Sirolimus (brand name Rapamune) is a macrolide mTOR immunosuppressant developed by Wyeth. It is mainly used for the prophylaxis of rejection after renal transplantation and the treatment of lymphangioleiomyomatosis. This article systematically introduces its indications, dosage, adverse reactions and safe administration specifications.
